[8] With rapamycin, inhibition of mTOR is due to the binding of rapamycin to the FK506 binding protein (FKBP12), which allosterically inhibits mTORC1
30 Additional Contributors Other conditions that can lead to CKD include 31-33 : Kidney damage caused by the long-term use of certain medications (see section titled What Medications Are Linked to Chronic Kidney Disease? below) Polycystic kidney disease, a genetic condition in which multiple large cysts form in the kidneys Autoimmune disorders such as lupus and Goodpastures disease, in which the kidneys undergo inflammatory damage Recurring or persistent kidney or systemic infections Long-term heavy metal exposure (eg, lead poisoning) Gout and high uric acid (bi-directional relationship) 4 Symptoms of Chronic Kidney Disease A major challenge with CKD is that it rarely causes symptoms before stages 4 and 5
20 mg in female arousal studies Subcutaneous injection: 0.75 mg, 1.25 mg, and 1.75 mg in Phase 2-3 female HSDD trials FDA-approved dose: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity Important: These are doses from completed clinical trials
LiuHTanMChengBWangSXiaoLZhuJet al
We can at least augment that effect, if not provide a mechanism to transition off the drug once its initial benefits are achieved
They shorten with every cell division
